1. Home
  2. Analysis

Traumatic intracranial haemorrhage and drugs of ingredients of metolazone - a phase IV clinical study of FDA data


Summary:

Traumatic intracranial haemorrhage is reported only by a few people who take drugs with ingredients of metolazone. This phase IV clinical study analyzes 17,049 people who have side effects while taking drugs with ingredients of metolazone from the the FDA. Among them, 2 have Traumatic intracranial haemorrhage. Find out below who they are, when they have Traumatic intracranial haemorrhage and more.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Diulo, Metolazone, Mykrox, Zaroxolyn.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 27, 2023

17,049 people reported to have side effects when taking drugs with ingredients of metolazone.
Among them, 2 people (0.01%) have Traumatic intracranial haemorrhage

What is Traumatic intracranial haemorrhage?

Traumatic intracranial haemorrhage (a bleeding in brain due to trauma) is found to be associated with 341 drugs and 187 conditions by eHealthMe.

Number of reports submitted per year:

Could drugs with ingredients of metolazone cause Traumatic intracranial haemorrhage?

Time on drugs with ingredients of metolazone when people have Traumatic intracranial haemorrhage *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 100 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Traumatic intracranial haemorrhage when taking drugs with ingredients of metolazone *:

  • female: 50 %
  • male: 50 %

Age of people who have Traumatic intracranial haemorrhage when taking drugs with ingredients of metolazone *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Conditions people have *:

  1. Psychotic Disorder: 2 people, 100.00%
  2. Hypertensive Heart Disease: 1 person, 50.00%

Other drugs people take *:

  1. Haldol: 2 people, 100.00%
  2. Aldactone: 2 people, 100.00%

Other side effects people have besides Traumatic intracranial haemorrhage *:

  1. Skull Fractured Base: 2 people, 100.00%
  2. Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 2 people, 100.00%
  3. Fall: 2 people, 100.00%
  4. Dehydration (dryness resulting from the removal of water): 2 people, 100.00%
  5. Acute Kidney Failure: 2 people, 100.00%
  6. Seizures (abnormal excessive or synchronous neuronal activity in the brain): 1 person, 50.00%
  7. Fainting (loss of consciousness and postural tone): 1 person, 50.00%
  8. Delirium Tremens (a psychotic condition typical of withdrawal in chronic alcoholics): 1 person, 50.00%
  9. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 50.00%
  10. Blood Creatinine Increased: 1 person, 50.00%

* Approximation only. Some reports may have incomplete information.

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drugs with ingredients of metolazone, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on metolazone. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.